Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Edratide in systemic lupus erythematosus (PRELUDE)
NCT00203151Phase 2Terminated
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Jul 2005
- Primary completion
- Feb 2007
- Modality
- Modified Peptides, Native Peptides
01
Overview
A Phase 2 trial of edratide in systemic lupus erythematosus (SLE), sponsored by Teva Pharmaceutical Industries Ltd.. Started Jul 2005; status: terminated.
02
Drugs
edratide
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT00203151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00203151.